The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Totally, if you think forward the interim results RNS is already going to be saying that H1 revenues are up over 50% on the previous year. We’re moving forward and upwards and the market is just going to take time to wake up. They just didn’t communicate well in the trading update.
Part of their fundraising strategy was to boost presence in North American market as well as diagnostic and veterinary according to this. Just the out working of that I suspect
https://www.dlapiper.com/en-us/news/2024/03/dla-piper-advises-leading-biotechnology-business
Agree, there was nothing new in terms of performance in this. The revenues were in line with broker predictions and market expectations. Key new positive info in here for me is:
Order book already beating last years revenues.
Additional revenues from master services agreement with global diagnostics company
Clients requesting multiple contracts and projects at a time.
It’s looking more optimistic for 2024/25 although not without challenges in cash.
I agreed with comments, we’re all here to help each other rather than be deconstructive. The way I see it there a challenges and big positives:
Positives:
- strong order book versus last year
- recruiting staff to key commercialisation roles
- partnership with global diagnostics company which is generating recurring orders already
- evidence of diversification from previous strategy
- world first technology being validated by worlds most prestigious cancer centre which had £7bn funding from US government last year.
- new class leading technologies, optimal, optiphage, AIMLAB, getting traction in market shortly after development
- other pipeline opportunities in development include Fusion being part of the future medicines institute being developed to strengthen r&d collaboration as part of Northern Ireland life sciences cluster. Hopefully word soon on that being funded.
- royalty and milestone entitlement in a range of projects that could generate future revenue.
- challenges
- cash runway less than a year and dependent on cash neutrality
- interest rate environment might slow biotech and VC recovery that was anticipated
- need to recruit staff to commercialise orders could slow recovery
- lack of corporate and investor comms strategy will probably keep share price depressed to a greater extent unless significant news comes